triamcinolone
Trade name: kenalog
Approved
Dec 3, 1957
Triamcinolone acetonide, sold under the brand name Kenalog among others, is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions. It is also injected into lesions to treat inflammation in some parts of the body, particularly the skin. In nasal spray form, it is used to treat allergic rhinitis. It is used for the treatment of macular edema associated with uveitis. It is a more potent derivative of triamcinolone, and is about eight times as potent as prednisone. — Wikipedia
Clinical trial activity
575 trials · 423 clinical orgs · 81 marketing orgs
Earliest trial started Sep 1, 1993 (NCT00000569)
Timeline
1950s
1960s
- Jan 4, 1960
Apothecon — NDA Secondary Org
- Jul 30, 1963
American Cyanamid — First NDA Organization
- Jul 30, 1963
American Cyanamid — NDA Organization
- Jul 29, 1969
Sandoz — NDA Secondary Org
1970s
- Apr 26, 1972
Astellas — Marketing Organization
- Jan 29, 1974
delcor — Marketing Organization
- Oct 11, 1974
Sun Pharmaceuticals — NDA Secondary Org
- Apr 22, 1975
Impax Laboratories — Marketing Organization
- Oct 16, 1975
Barr Laboratories — Marketing Organization
- May 24, 1976
Teva — Marketing Organization
- Jan 24, 1977
Watson Pharmaceuticals — Marketing Organization
- Mar 9, 1978
Fougera — Marketing Organization
- Jun 23, 1978
Ivax — Marketing Organization
- Apr 10, 1979
Taro Pharmaceuticals — Marketing Organization
1980s
- Apr 9, 1981
Padagis Us — Marketing Organization
- Apr 23, 1982
AbbVie — NDA Secondary Org
- Jun 4, 1982
Actavis — Marketing Organization
- Jul 30, 1982
Sandoz — Marketing Organization
- Sep 8, 1982
Alpharma — Marketing Organization
- Mar 25, 1983
Savage Labs — Marketing Organization
- May 9, 1983
Ambix — Marketing Organization
- Mar 19, 1984
Crown Laboratories, Inc. — Marketing Organization
- Apr 1, 1985
Wockhardt — Marketing Organization
- May 28, 1985
ACP Nimble — Marketing Organization
- May 28, 1985
Cosette — Marketing Organization
- Oct 16, 1987
Parnell Pharmaceuticals — NDA Secondary Org
- Dec 23, 1988
G & W Laboratories Inc. — Marketing Organization
- Feb 21, 1989
Topiderm — Marketing Organization
1990s
- Jul 11, 1991
Sanofi-Aventis — NDA Secondary Org
- Jul 11, 1991
Sanofi — Marketing Organization
- Jul 11, 1991
Sanofi — NDA Secondary Org
- Jan 1, 1993
Earliest Phase 3 Sponsor(trial)
- Mar 23, 1995
CMP Therapeutics Ltd — Marketing Organization
2000s
- Feb 4, 2000
Lupin — NDA Secondary Org
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
- Jun 9, 2006
Lannett Company, Inc. — Marketing Organization
- Jun 9, 2006
Mylan — Marketing Organization
- Jun 9, 2006
Micro Labs Ltd India — Marketing Organization
- Dec 13, 2006
Allied Pharmaceutical Services — Marketing Organization
- Dec 13, 2006
Saptalis Pharmaceuticals — Marketing Organization
- Nov 29, 2007
Alcon — NDA Secondary Org
- Nov 29, 2007
Novartis — NDA Secondary Org
- Nov 29, 2007
Novartis — Marketing Organization
- Nov 29, 2007
Nestle — NDA Secondary Org
- Nov 29, 2007
Harrow Health — Marketing Organization
- Jun 16, 2008
Allergan — NDA Secondary Org
- Jun 16, 2008
GlaxoSmithKline — NDA Secondary Org
- Jul 30, 2009
Perrigo — Marketing Organization
2010s
- Jul 1, 2010
Lyne Laboratories — Marketing Organization
- May 8, 2013
Akorn, Inc. — Marketing Organization
- May 8, 2013
Epic Pharma Llc — Marketing Organization
- May 13, 2016
Teligent Pharmaceuticals — Marketing Organization
- Jul 7, 2016
Pharmaceutical Associates — Marketing Organization
- Oct 26, 2016
Dr. Reddy's Laboratories — Marketing Organization
- Dec 29, 2016
ANDA Repository — Marketing Organization
- Feb 1, 2017
Chartwell Pharmaceuticals — Marketing Organization
- Aug 22, 2017
Glenmark Pharmaceuticals — Marketing Organization
- Sep 8, 2017
Rising Pharmaceuticals — Marketing Organization
- Oct 6, 2017
Flexion Therapeutics — NDA Secondary Org
- Oct 6, 2017
Pacira Pharmaceuticals — Marketing Organization
- Oct 6, 2017
Pacira Pharmaceuticals — NDA Secondary Org
- Dec 11, 2017
Amneal Pharmaceuticals — Marketing Organization
- Dec 26, 2017
Alkem Labs Ltd — Marketing Organization
- Jan 29, 2018
Strides Pharma Science — Marketing Organization
- May 18, 2018
Macleods Pharmaceuticals, Ltd — Marketing Organization
- May 18, 2018
Neogen — Marketing Organization
- May 31, 2018
Lupin — Marketing Organization
- Oct 12, 2018
Novel Anti-Infective Technologies, LLC — Marketing Organization
- Nov 8, 2018
Zydus Discovery DMCC — Marketing Organization
- Nov 8, 2018
Cadila Healthcare — Marketing Organization
- Nov 18, 2019
Vitruvias Therapeutics — Marketing Organization
- Nov 29, 2019
Encube Ethicals Pvt. Ltd. — Marketing Organization
2020s
- Jul 1, 2020
Quagen Pharma — Marketing Organization
- Jul 14, 2020
Torrent Pharmaceuticals Limited — Marketing Organization
- Nov 11, 2020
Cintex Services — Marketing Organization
- Mar 31, 2021
Alembic — Marketing Organization
- Oct 22, 2021
Clearside Biomedical, Inc. — Marketing Organization
- Oct 22, 2021
Bausch & Lomb — Marketing Organization
- Oct 22, 2021
Bausch Health Companies — NDA Secondary Org
- Jan 19, 2022
LONG GROVE PHARMS — Marketing Organization
- Jul 5, 2022
Eugia Pharma — Marketing Organization
- Jan 19, 2023
Apotex — Marketing Organization
Indications
Approved for
- Adrenal Hyperplasia, Congenital (approved 1957)
- Anemia
- Arteritis
- Arthritis, Gouty
- Arthritis, Rheumatoid
- Asthma
- Bursitis
- Dermatitis
- Dermatitis Herpetiformis (approved 1957)
- Endophthalmitis
- Lymphoma (approved 1957)
- Multiple Sclerosis
- Mycoses
- Nasal Obstruction
- Osteoarthritis
- Pain
- Rhinitis, Allergic, Perennial (approved 1996)
- Rhinitis, Allergic, Seasonal (approved 1957)
- Serum Sickness
- Skin Diseases
- Tennis Elbow
- Tenosynovitis
- Tuberculosis, Pulmonary
- Uveitis (approved 1957)
- Wounds and Injuries
Studied for
- Abdominal Injuries · Phase 4
- Abdominal Pain · Phase 4
- Acne Vulgaris · Phase 2
- Acute Generalized Exanthematous Pustulosis · Phase 2
- Adenomyosis · Early Phase 1
- Adipose Tissue · Phase 2
- Adiposity · Phase 4
- Adrenal Insufficiency · Phase 4
- Alopecia · Phase 4
- Alopecia Areata · Phase 4
- Anesthesia, Epidural · Phase 4
- Anterior Cruciate Ligament Injuries · Phase 2
- Arthralgia · Phase 4
- Arthritis · Phase 4
- Arthritis, Gouty · Phase 3
- Arthritis, Juvenile · Phase 4
- Arthritis, Psoriatic · Phase 4
- Arthritis, Rheumatoid · Phase 2
- Arthroplasty, Replacement, Knee · Phase 4
- Asthma · Phase 2
- Blood Pressure · Phase 3
- Bone Density · Phase 4
- Bone Diseases · Phase 4
- Breast Neoplasms · Phase 2
- Bursitis · Phase 4
- Carpal Tunnel Syndrome · Phase 4
- Cataract · Phase 4
- Cell- and Tissue-Based Therapy · Phase 1/Phase 2
- Central Serous Chorioretinopathy · Phase 2/Phase 3
- Cervix Uteri · Phase 4
- Chalazion · Phase 3
- Cholecalciferol · Early Phase 1
- Choroidal Effusions · Phase 4
- Choroidal Neovascularization · Phase 3
- Chronic Pain · Phase 4
- Cicatrix, Hypertrophic · Phase 4
- Complex Regional Pain Syndromes · Phase 4
- Connective Tissue Diseases · Phase 4
- Constriction, Pathologic · Phase 3
- Contracture · Phase 4
- Corneal Edema · Phase 3
- Coronary Disease · Phase 2
- Cough · Phase 3
- Cystitis, Interstitial · Phase 4
- Cysts · Phase 2
- De Quervain Disease · Phase 3
- Dermatitis, Allergic Contact · Phase 2/Phase 3
- Dermatitis, Atopic · Phase 4
- Dermatitis, Contact · Phase 4
- Dermatitis, Occupational · Phase 4
- Dermatology · Phase 4
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Retinopathy · Phase 3
- Drug Delivery Systems · Phase 2/Phase 3
- Drug Interactions · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Dupuytren Contracture · Phase 4
- Dyspareunia · Phase 4
- Eczema · Phase 4
- Elbow · Phase 2/Phase 3
- Endodontics · Phase 4
- Esophageal Stenosis · Phase 4
- Exanthema · Phase 2
- Exercise · Phase 4
- Eye Diseases · Phase 3
- Facial Pain · Phase 4
- Fat Body · Phase 4
- Fibroma · Phase 4
- Fibrosis · Phase 4
- Fissure in Ano · Phase 4
- Flail Chest · Phase 2/Phase 3
- Gastrointestinal Microbiome · Phase 2/Phase 3
- General Surgery · Phase 2/Phase 3
- Geographic Atrophy · Phase 2
- Glaucoma · Phase 4
- Glioblastoma · Phase 2
- Glucocorticoids · Phase 3
- Gout · Phase 4
- Granulation Tissue · Phase 2/Phase 3
- Granulomatous Mastitis · Phase 1
- Graves Ophthalmopathy · Phase 4
- Hand Dermatoses · Phase 2
- Headache · Phase 4
- Hearing Loss, Sensorineural · Phase 2
- Hemorrhoids · Phase 4
- Hidradenitis Suppurativa · Phase 4
- Humeral Fractures · Early Phase 1
- Infections · Phase 4
- Inflammation · Phase 4
- Injections · Phase 4
- Intraocular Pressure · Phase 4
- Intravitreal Injections · Phase 2/Phase 3
- Joint Diseases · Phase 4
- Keloid · Phase 4
- Knee · Phase 4
- Knee Injuries · Phase 4
- Laryngeal Diseases · Early Phase 1
- Leber Congenital Amaurosis · Phase 1/Phase 2
- Leiomyoma · Early Phase 1
- Lens Diseases · Phase 3
- Lichen Planus · Phase 2
- Lichen Planus, Oral · Phase 4
- Ligaments · Phase 4
- Ligaments, Articular · Phase 4
- Low Back Pain · Phase 4
- Lumbar Vertebrae · Phase 4
- Lung Diseases · Phase 3
- Lung Diseases, Obstructive · Phase 3
- Lymphoma, T-Cell · Phase 2
- Lymphoma, T-Cell, Cutaneous · Phase 2
- Macular Degeneration · Phase 4
- Macular Edema · Phase 4
- Magnetic Resonance Imaging · Phase 2
- Melanoma · Phase 4
- Melanosis · Phase 2/Phase 3
- Meniscus · Phase 4
- Mesenchymal Stem Cells · Phase 1/Phase 2
- Morton Neuroma · Phase 4
- Mucositis · Phase 1/Phase 2
- Musculoskeletal Diseases · Phase 4
- Mycosis Fungoides · Phase 2
- Myocardial Infarction · Phase 2
- Myocardial Ischemia · Phase 2
- Myofascial Pain Syndromes · Phase 4
- Myofascial Release Therapy · Phase 4
- Nail Diseases · Phase 4
- Nasal Obstruction · Phase 4
- Nasal Polyps · Phase 2/Phase 3
- Neck Pain · Phase 4
- Neoplasms · Phase 4
- Neoplasms by Histologic Type · Phase 4
- Neoplasms, Connective and Soft Tissue · Phase 4
- Neoplasms, Connective Tissue · Phase 4
- Neoplasms, Fibrous Tissue · Phase 4
- Neovascularization, Pathologic · Phase 2/Phase 3
- Nerve Block · Phase 3
- Neuralgia · Early Phase 1
- Neuroma, Acoustic · Phase 1
- Ophthalmology · Phase 2/Phase 3
- Optic Neuropathy, Ischemic · Phase 3
- Oral Submucous Fibrosis · Phase 3
- Orbital Pseudotumor · Phase 3
- Osteoarthritis, Hip · Phase 3
- Osteoarthritis, Knee · Phase 4
- Otitis Media · Phase 3
- Otitis Media with Effusion · Phase 3
- Pancreatitis, Chronic · Phase 3
- Panuveitis · Phase 3
- Papilledema · Early Phase 1
- Paranasal Sinus Diseases · Phase 3
- Paresis · Phase 2
- Pars Planitis · Phase 2/Phase 3
- Pelvic Organ Prolapse · Phase 4
- Pemphigoid, Benign Mucous Membrane · Phase 2/Phase 3
- Pemphigus · Phase 3
- Pentoxifylline · Phase 4
- Pharmacokinetics · Phase 4
- Physical Functional Performance · Phase 4
- Pigmentation Disorders · Phase 2
- Polyps · Phase 2
- Postoperative Care · Phase 4
- Postoperative Complications · Phase 4
- Postoperative Pain · Phase 4
- Precancerous Conditions · Phase 2
- Prostatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Prurigo · Phase 3
- Pruritus · Phase 2
- Psoriasis · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 3
- Quality of Life · Phase 4
- Radiculopathy · Phase 4
- Rectal Fistula · Phase 4
- Retinal Detachment · Phase 4
- Retinal Diseases · Phase 4
- Retinal Vein Occlusion · Phase 4
- Retinoschisis · Phase 4
- Rhinitis · Phase 3
- Rhinitis, Allergic · Phase 4
- Rhinitis, Allergic, Perennial · Phase 4
- Rhinitis, Allergic, Seasonal · Phase 3
- Rotator Cuff Injuries · Phase 4
- Shoulder Impingement Syndrome · Phase 4
- Shoulder Injuries · Phase 4
- Shoulder Pain · Phase 4
- Sinusitis · Phase 4
- Sleep Apnea, Obstructive · Phase 3
- Spinal Stenosis · Phase 4
- Spondylosis · Phase 4
- Sprains and Strains · Phase 4
- Stem Cells · Phase 4
- Steroids · Phase 3
- Stomach Diseases · Phase 4
- Stomatitis, Aphthous · Phase 2
- Stroke · Phase 4
- Synovitis · Phase 4
- Temporomandibular Joint · Phase 4
- Tendinopathy · Phase 4
- Tennis Elbow · Phase 4
- Tenosynovitis · Phase 4
- Therapeutics · Phase 2
- Thyroid Gland · Phase 2
- Tibial Meniscus Injuries · Phase 2
- Tissues · Phase 3
- Traumatology · Phase 3
- Triamcinolone · Phase 4
- Triamcinolone Acetonide · Phase 3
- Trigger Finger Disorder · Phase 4
- Uveitis · Phase 4
- Uveitis, Anterior · Phase 3
- Uveitis, Intermediate · Phase 3
- Uveitis, Posterior · Phase 3
- Uveomeningoencephalitic Syndrome · Phase 2/Phase 3
- Vascular Diseases · Phase 2
- Vasoconstriction · Phase 1
- Vitamin E · Phase 4
- Vitiligo · Phase 2/Phase 3
- Vitrectomy · Phase 3
- Vitreoretinopathy, Proliferative · Phase 4
- Vocal Cord Dysfunction · Phase 4
- Vocal Cords · Phase 2
- Wet Macular Degeneration · Phase 4
- Wound Healing · Phase 2/Phase 3
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Combination products
Approval history
- approvedPriority reviewDec 3, 1957
Chemistry & pharmacology
SMILES
CC(=O)OCC(=O)[C@@]1(O)[C@H](OC(C)=O)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C- Mol. weight
- 478.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Discontinued
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- WikipediaTriamcinolone acetonide ↗
- ChEMBLCHEMBL1504 ↗
- ChEMBLCHEMBL1451 ↗
- ChEMBLCHEMBL1200878 ↗
- ChEMBLCHEMBL1200449 ↗
- WikipediaTriamcinolone hexacetonide ↗
- WikipediaTriamcinolone ↗
- NCATSF446C597KA ↗
- ChEMBLCHEMBL2105798 ↗
- NCATS1ZK20VI6TY ↗
Also known as
- (11 beta, 16 alpha)-21-(3,3-dimethyl-1-oxobutoxy)-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy)) pregna-1,4-diene-3,20-dione
- 11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
- 11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
- 9-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-(3,3-dimethylbutyrate)
- 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
- 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
- 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
- 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
- 9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
- 9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
- 9α-fluoro-16α-hydroxyprednisolone
- 9α-fluoro-16α-hydroxyprednisolone
- adcortyl
- adcortyl
- adcortyl
- adcortyl in orabase
- allernaze
- allernaze
- allernaze
- aristicort
- aristocort
- aristocort
- aristocort
- aristocort
- aristocort a
- aristocort a
- aristocort diacetate
- aristogel
- aristogel
- aristospan
- aristospan
- aristospan
- aristospan
- aristospan
- audicort
- aureocort
- azmacort
- azmacort
- cl 34433
- cl-34433
- cl-34433
- cl-34433
- cls-ta
- delphicort
- delphicort
- fluoxiprednisolone
- fluoxiprednisolone
- fluoxyprednisolone
- fluoxyprednisolone
- flutex
- fx006
- fx006
- gppe ear dps cap
- gppe ear oint
- gramicidin, neomycin sulfate, nystatin, triamcinolone acetonide drug combination
- hexatrione
- kenacomb
- kenacort
- kenacort
- kenacourt
- kenacourt
- kenalog
- kenalog
- kenalog
- kenalog-10
- kenalog-40
- kenalog-40
- kenalog-h
- kenalog-h
- kenalog in orabase
- kenalog in orabase
- lederspan
- lederspan
- mycolog
- nasacort
- nasacort
- nasacort
- nasacort
- nasacort
- nasacort
- nasacort aq
- nasacort aq
- nasacort hfa
- nasacort hfa
- nystadermal
- oracort
- oralone
- orion
- orion
- pevaryl t.c.
- polcartolone
- polcortolon
- polcortolon
- polcortolon
- polcortolon
- remiderm
- remotic
- rodinolone
- shincort
- silderm
- tac ointment
- tatba
- tatba
- tedarol
- tedarol
- tiamcinolonum
- tiamcinolonum
- tibicorten
- tramcinolone
- triacet
- triacet
- triacort
- triadcortyl
- tri-adcortyl
- tri-adcortyl
- triadcortyl otic
- triamcenolone
- triamcinalone
- triamcinalone
- triamcinlon
- triamcinolon
- triamcinolona
- triamcinolona
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone
- triamcinolone acetonide
- triamcinolone acetonide
- triamcinolone acetonide
- triamcinolone acetonide
- triamcinolone acetonide
- triamcinolone acetonide
- triamcinolone acetonide in absorbase
- triamcinolone acetonide in absorbase
- triamcinolone benetonide
- triamcinolone benetonide
- triamcinolone benetonide
- triamcinolone benetonide
- triamcinolone diacetate
- triamcinolone diacetate
- triamcinolone diacetate
- triamcinolone diacetate
- triamcinolone diacetate
- triamcinolone diacetate
- triamcinolone diacetate
- triamcinolone diacetate
- triamcinolone hexacetonide
- triamcinolone hexacetonide
- triamcinolone hexacetonide
- triamcinolone hexacetonide
- triamcinolone hexacetonide
- triamcinolone hexacetonide
- triamcinolone hexacetonide
- triamcinolone hexacetonide
- triamcinolonum
- triamcinolonum
- triatex
- triatex
- triderm
- triderm
- triesence
- triesence
- tri-nasal
- tri-nasal
- trivaris
- trivaris
- trymex
- trymex
- vetalog
- vetalog
- volon
- volon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07277998 | N/A | Mar 31, 2026 | Karachi Medical and Dental College |
| NCT07100145 | Phase 4 | Jan 1, 2026 | Ain Shams University |
| NCT07228104 | Phase 3 | Jan 1, 2026 | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT07283874 | Phase 4 | Dec 31, 2025 | Assiut University |
| NCT07201766 | N/A | Dec 2, 2025 | King Edward Medical University |
| NCT07168148 | Phase 2 | Nov 10, 2025 | Washington University in St. Louis |
| NCT07189572 | Phase 3 | Oct 31, 2025 | Chinese Academy of Medical Sciences, Huazhong University of Science and Technology, Sun Yat-Sen University |
| NCT07131813 | Phase 4 | Oct 10, 2025 | All India Institute of Medical Sciences |
| NCT07242846 | Phase 4 | Oct 2, 2025 | Nigde Omer Halisdemir University |
| NCT07151417 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2025 | United States Army |
| NCT07134075 | Phase 2 | Aug 25, 2025 | Fudan University, Jiao Tong University |
| NCT06761768 | N/A | Aug 1, 2025 | Government of Taiwan, Tri-Service General Hospital |
| NCT06977568 | Phase 2 | Jul 25, 2025 | Pacira Pharmaceuticals |
| NCT06985537 | Phase 1 | Jun 30, 2025 | Assiut University |
| NCT06981767 | Phase 2 | Jun 15, 2025 | Cairo University |
| NCT06993337 | Phase 2 | Jun 15, 2025 | Cairo University |
| NCT06994520 | Phase 2 | May 1, 2025 | KhonKaen University |
| NCT06758739 | Phase 3 | Apr 30, 2025 | Services Institute of Medical Sciences, Pakistan |
| NCT06935877 | Phase 4 | Apr 25, 2025 | Shin Kong Wu Ho-Su Memorial Hospital |
| NCT06897969 | Phase 4 | Apr 1, 2025 | Nishtar Medical University |
Organizations
Research & Development (423)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cairo University | Academic/Hospital | 18 | 18 | 5 | 2007 |
| Flexion Therapeutics | For profit | 17 | 15 | 3 | 2012 |
| Shahid Beheshti University of Medical Sciences | Academic/Hospital | 16 | 15 | 4 | 2001 |
| University of Sao Paulo | Academic/Hospital | 15 | 14 | 4 | 2004 |
| Assiut University | Academic/Hospital | 14 | 13 | 5 | 2016 |
| National Eye Institute (NEI) | Government | 14 | 8 | 4 | 2003 |
| Novartis | For profit | 9 | 7 | 2 | 2003 |
| United States Army | Government | 9 | 9 | 5 | 2000 |
| Al Azhar University | Academic/Hospital | 8 | 8 | 4 | 2020 |
| Alexandria University | Academic/Hospital | 8 | 8 | 3 | 2018 |
| Mayo Clinic | Academic/Hospital | 8 | 7 | 5 | 2005 |
| Taipei Veteran General hospital | Government | 8 | 8 | 1 | 2012 |
| Allergan | For profit | 7 | 0 | 3 | 2004 |
| Clearside Biomedical, Inc. | For profit | 7 | 7 | 2 | 2013 |
| Mahidol University | Academic/Hospital | 7 | 6 | 3 | 2009 |
| Northwestern University | Academic/Hospital | 6 | 6 | 3 | 2013 |
| Sanofi | For profit | 6 | 6 | 3 | 2003 |
| Tanta University | Academic/Hospital | 6 | 6 | 3 | 2020 |
| Benha University | Academic/Hospital | 5 | 5 | 2 | 2020 |
| Genentech | For profit | 5 | 0 | 4 | 2007 |
Marketing (116)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ACP Nimble | For profit | MKTG | May 28, 1985 |
| ANDA Repository | For profit | MKTG | Dec 29, 2016 |
| AbbVie | For profit | NDA2 | Apr 23, 1982 |
| Actavis | For profit | MKTG | Jun 4, 1982 |
| Akorn, Inc. | For profit | MKTG | May 8, 2013 |
| Alcon | For profit | NDA2 | Nov 29, 2007 |
| Alembic | For profit | MKTG | Mar 31, 2021 |
| Alembic | For profit | SYN | Mar 31, 2021 |
| Alkem Labs Ltd | For profit | MKTG | Dec 26, 2017 |
| Allergan | For profit | NDA2 | Jun 16, 2008 |
| Allied Pharmaceutical Services | For profit | MKTG | Dec 13, 2006 |
| Alpharma | For profit | MKTG | Sep 8, 1982 |
| Ambix | For profit | MKTG | May 9, 1983 |
| American Cyanamid | For profit | NDA | Jul 30, 1963 |
| Amneal Pharmaceuticals | For profit | MKTG | Dec 11, 2017 |
| Amneal Pharmaceuticals | For profit | SYN | Feb 15, 2018 |
| Amneal Pharmaceuticals | For profit | SYN | Dec 11, 2017 |
| Apotex | For profit | MKTG | Jan 19, 2023 |
| Apothecon | For profit | NDA2 | Jan 4, 1960 |
| Astellas | For profit | NDA2 | Dec 3, 1957 |
| Astellas | For profit | MKTG | Apr 26, 1972 |
| Barr Laboratories | For profit | MKTG | Oct 16, 1975 |
| Bausch & Lomb | For profit | MKTG | Oct 22, 2021 |
| Bausch Health Companies | For profit | NDA2 | Oct 22, 2021 |
| CMP Therapeutics Ltd | For profit | MKTG | Mar 23, 1995 |
| Cadila Healthcare | For profit | MKTG | Nov 8, 2018 |
| Chartwell Pharmaceuticals | For profit | MKTG | Feb 1, 2017 |
| Cintex Services | For profit | MKTG | Nov 11, 2020 |
| Clearside Biomedical, Inc. | For profit | MKTG | Oct 22, 2021 |
| Cosette | For profit | MKTG | May 28, 1985 |
| Crown Laboratories, Inc. | For profit | MKTG | Mar 19, 1984 |
| Crown Laboratories, Inc. | For profit | SYN | Dec 26, 2017 |
| Dr. Reddy's Laboratories | For profit | SYN | Oct 26, 2016 |
| Dr. Reddy's Laboratories | For profit | MKTG | Oct 26, 2016 |
| Encube Ethicals Pvt. Ltd. | For profit | MKTG | Nov 29, 2019 |
| Epic Pharma Llc | For profit | MKTG | May 8, 2013 |
| Eugia Pharma | For profit | MKTG | Jul 5, 2022 |
| Flexion Therapeutics | For profit | NDA2 | Oct 6, 2017 |
| Fosun | For profit | NDA2 | Mar 12, 1959 |
| Fougera | For profit | MKTG | Mar 9, 1978 |
| Fougera | For profit | SYN | Oct 8, 1985 |
| G & W Laboratories Inc. | For profit | MKTG | Dec 23, 1988 |
| G & W Laboratories Inc. | For profit | SYN | May 28, 1985 |
| GlaxoSmithKline | For profit | NDA2 | Jun 16, 2008 |
| Glenmark Pharmaceuticals | For profit | MKTG | Aug 22, 2017 |
| Glenmark Pharmaceuticals | For profit | SYN | Jun 23, 2016 |
| Harrow Health | For profit | MKTG | Nov 29, 2007 |
| Impax Laboratories | For profit | MKTG | Apr 22, 1975 |
| Ivax | For profit | MKTG | Jun 23, 1978 |
| LONG GROVE PHARMS | For profit | MKTG | Jan 19, 2022 |
| Lannett Company, Inc. | For profit | MKTG | Jun 9, 2006 |
| Lupin | For profit | NDA2 | Feb 4, 2000 |
| Lupin | For profit | MKTG | May 31, 2018 |
| Lupin | For profit | SYN | Feb 1, 2017 |
| Lyne Laboratories | For profit | MKTG | Jul 1, 2010 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | May 18, 2018 |
| Micro Labs Ltd India | For profit | SYN | Jun 9, 2006 |
| Micro Labs Ltd India | For profit | MKTG | Jun 9, 2006 |
| Morton Grove Pharmaceuticals | For profit | MKTG | — |
| Mylan | For profit | SYN | Oct 23, 1958 |
| Mylan | For profit | MKTG | Jun 9, 2006 |
| Mylan | For profit | SYN | Oct 23, 1958 |
| Mylan | For profit | SYN | Nov 2, 2022 |
| Mylan | For profit | NDA2 | Oct 23, 1958 |
| Neogen | For profit | MKTG | May 18, 2018 |
| Nestle | For profit | NDA2 | Nov 29, 2007 |
| Novartis | For profit | NDA2 | Nov 29, 2007 |
| Novartis | For profit | MKTG | Nov 29, 2007 |
| Novel Anti-Infective Technologies, LLC | For profit | MKTG | Oct 12, 2018 |
| Pacira Pharmaceuticals | For profit | MKTG | Oct 6, 2017 |
| Pacira Pharmaceuticals | For profit | NDA2 | Oct 6, 2017 |
| Padagis Us | For profit | SYN | Apr 13, 2015 |
| Padagis Us | For profit | SYN | Apr 9, 1981 |
| Padagis Us | For profit | MKTG | Apr 9, 1981 |
| Parnell Pharmaceuticals | For profit | NDA2 | Oct 16, 1987 |
| Perrigo | For profit | SYN | Jul 30, 2009 |
| Perrigo | For profit | MKTG | Jul 30, 2009 |
| Perrigo | For profit | SYN | Apr 9, 1981 |
| Perrigo | For profit | SYN | Apr 13, 2015 |
| Perrigo | For profit | SYN | Jul 30, 2009 |
| Pharmaceutical Associates | For profit | MKTG | Jul 7, 2016 |
| Pharmaderm | For profit | MKTG | — |
| Pharmafair | For profit | MKTG | — |
| Puracap Pharmaceutical | For profit | MKTG | — |
| Quagen Pharma | For profit | MKTG | Jul 1, 2020 |
| Rising Pharmaceuticals | For profit | SYN | Dec 29, 2016 |
| Rising Pharmaceuticals | For profit | MKTG | Sep 8, 2017 |
| Roxane Laboratories | For profit | MKTG | — |
| Sandoz | For profit | MKTG | Jul 30, 1982 |
| Sandoz | For profit | SYN | May 27, 2009 |
| Sandoz | For profit | NDA2 | Jul 29, 1969 |
| Sandoz | For profit | SYN | Jul 29, 1969 |
| Sanofi | For profit | MKTG | Jul 11, 1991 |
| Sanofi | For profit | NDA2 | Jul 11, 1991 |
| Sanofi-Aventis | For profit | NDA2 | Jul 11, 1991 |
| Saptalis Pharmaceuticals | For profit | MKTG | Dec 13, 2006 |
| Savage Labs | For profit | MKTG | Mar 25, 1983 |
| Solvay | For profit | MKTG | — |
| Strides Pharma Science | For profit | MKTG | Jan 29, 2018 |
| Sun Pharmaceuticals | For profit | NDA2 | Oct 11, 1974 |
| Taro Pharmaceuticals | For profit | MKTG | Apr 10, 1979 |
| Taro Pharmaceuticals | For profit | SYN | Sep 30, 1994 |
| Teligent Pharmaceuticals | For profit | MKTG | May 13, 2016 |
| Teligent Pharmaceuticals | For profit | SYN | May 13, 2016 |
| Teva | For profit | MKTG | May 24, 1976 |
| Teva | For profit | SYN | Oct 5, 2018 |
| Teva | For profit | SYN | Mar 11, 1974 |
| Topiderm | For profit | MKTG | Feb 21, 1989 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Jul 14, 2020 |
| Vitruvias Therapeutics | For profit | MKTG | Nov 18, 2019 |
| Watson Pharmaceuticals | For profit | MKTG | Jan 24, 1977 |
| Wockhardt | For profit | MKTG | Apr 1, 1985 |
| Zydus Discovery DMCC | For profit | MKTG | Nov 8, 2018 |
| Zydus Discovery DMCC | For profit | SYN | Nov 8, 2018 |
| delcor | For profit | NDA2 | Jan 14, 1958 |
| delcor | For profit | MKTG | Jan 29, 1974 |